Spondyloarthritis & psoriatic arthritis
Entheseal tissue signature in response to IL-17A inhibition in psoriatic arthritis: results from the EBIO entheseal biopsy study
Authors' conclusion
These findings underline the pivotal role of IL-17A in enthesitis, showing that IL-17A inhibition profoundly modulates the tissue microenvironment of entheses in PsA.
Study context
- Population
- Patients with active psoriatic arthritis (PsA) and enthesitis of the lateral epicondyle
- Participants
- 10 patients
- Comparison
- Entheseal tissue before vs after 24 weeks of IL-17A inhibition
- Outcome
- Cellular and molecular entheseal responses to IL-17A inhibition (IMC, spatial transcriptomics)
- Follow-up
- 24 weeks
Methodological detailsprospective, interventional, phase 4, single-group before–after
- Prospective
- Interventional
- Phase 4
- Single-group before–after
Main finding
As reported in the abstract
24 weeks
- Significant reductions of enthesitis-related immune cells, in particular IL-17-producing CD4, CD8, CD4neg/CD8neg T cells, granulocytes and innate lymphoid cells type 3 (imaging mass cytometry (IMC))
- CD200+DKK3+ fibroblasts and innate lymphoid cells type 2 expanded and formed an anti-inflammatory niche upon treatment (spatial transcriptomics)
- Decreased osteoblast differentiation markers
Further findings
Clinical response (Disease Activity in Psoriatic Arthritis (DAPSA), Spondyloarthritis research consortium of canada (SPARCC) score, power Doppler sonography) · 24 weeks
- Patients clinically responding to treatment
- 9/10
Original publication
Entheseal tissue signature in response to IL-17A inhibition in psoriatic arthritis: results from the EBIO entheseal biopsy study. Ann Rheum Dis. Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →